Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies

Drugs

Volumn 60, Issue 4, 2000, Pages 895-924

  Culy, C R ^a   Clemett, D ^a   Wiseman, L R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; METASTASIS; NEUROPATHY; OVARY CANCER; PHARMACODYNAMICS; REVIEW;

EID: 0033766638     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060040-00005     Document Type: Review

References (143)

1. Comparative adverse effect profiles of platinum drags
2. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update
3. Oxaliplatin: A review of its use in the management of metastatic colorectal cancer
4. Oxaliplatin: Mechanism of action and antineoplastic activity
5. Oxaliplatin: A review of preclinical and clinical studies
6. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
7. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian cancer cell lines
8. Specificity of platinum-DNA adduct repair
9. Computer modelling of the primary cisplatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition
10. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells
11. Oxaliplatin (OxPt) effects on naked and intracellular DNA
12. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
13. Induction of γ-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line
14. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells
15. The role of DNA mismatch repair in platinum drug resistance
16. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
17. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
18. Antitumour activity of oxaliplatin in neuroblastoma cell lines
19. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
20. Comparative effects of a new platinum analog [trans-1-diamine-cyclohexane oxalato-platinum; L-OHP] with CDDP on various cells: Correlation with intracellular accumulation
21. Accumulation of cis-diammine-dichloroplatinum(II) and platinum analogues by platinum-resistant murine leukaemia cells in vitro
22. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drag-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel
23. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines
24. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin
25. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
26. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data
27. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
28. Supraaaditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
29. Activity of oxaliplatin against human tumor colony-forming units
30. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane) platinum (II): New experimental data
31. Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
32. Antitumour activity of L-OHP in mice
33. Oxaliplatin and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers
34. Evaluation of oxaliplatintirapazamine-taxol combinations in the MV-522 human lung carcinoma xenograft model
35. Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia
36. Intracellular glutathione and cytotoxicity of platinum complexes
37. Biological properties of ten human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes
38. Clinical pharmacokinetics of oxaliplatin: A critical review
39. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects
40. Pharmacokinetics, urinary and fecal excretion of oxaliplatin in cancer patients
41. Clinical pharmacokinetics of oxaliplatin
42. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
43. Variations in platinum plasma levels depending on chronomodulated oxaliplatin peak time
44. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer
45. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
46. Pharmacokinetics of oxaliplatin in special populations
47. Oxaliplatin (L-OHP) does NOT influence the pharmacokinetics of 5-fluorouracil (5-FU)
48. Influence of oxaliplatin on 5-fluorouracil pharmacokinetics. Clinical consequences
49. Pharmacokinetic interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP)
50. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
51. Pharmacokinetics (PK) of the oxaliplatin (LOHP)/topotecan (T) combination: Preliminary data of an ongoing phase I trial
52. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with avanced colorectal cancer
53. Pharmacokinetic (PK) of Tomudex (raltitrexed) (T) and oxaliplatin (O) combination: Preliminary results of an ongoing phase I study
54. Reporting results of cancer treatment
55. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
56. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
57. Final efficacy update at 7 years of flat vs chronomodulated infusion (Chrono) of oxaliplatin, 5-fluorouracil and leucovorin as first line treatment of metastatic colorectal cancer
58. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
59. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
60. Raltitrexed ('Tomudex') plus oxaliplatin: An active combination for first-line chemotherapy in patients with metastatic colorectal cancer
61. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
62. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
63. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
64. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
65. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
66. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/-FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program
67. Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer
68. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study
69. Biweekly oxaliplatin (L-OHP) with high-dose leucovorin (LV) and 5-fluorouracil (5-FU) in irinotecan pretreated patients with advanced colorectal cancer (ACC)
70. Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer. The GERCOD [in French]
71. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
72. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
73. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
74. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
75. Combined irinotecan, oxaliplatin, 5-FU in patients (PTS) with metastatic colorectal cancer (MCC)
76. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectai cancer
77. Oxaliplatin (L-OHP) and irinotecan (CPT-11) phase I/II studies: Results in 5 FU refractory (FR) colorectal cancer (CRC) patients (pts)
78. Final results of CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-I1/LV5FU2 + LOHP in 5FU resistant advanced colorectal cancer (ACRC)
79. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)
80. Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer
81. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-flourouracil i.v. bolus every two weeks: A dose finding study in advanced previously treated colorectal carcinoma
82. Oxaliplatin + tomudex in patients with advanced colorectal cancer: A disease-oriented phase I/II trial
83. Expanded access program (EAP) single agent oxaliplatin (L-OHP) in fluoropyrimidines resistant advanced colorectal cancer (FRAC) patients (pts)
84. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
85. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
86. Contribution of second line oxaliplatin (OXA)-chronomodulated 5-flourouracil-folinic acid (CM-5-FU-FA) and surgery to survival in metastatic colorectal cancer in patients (MCC pts) [abstract no. 1050]
87. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
88. Factors influencing the natural history of colorectal liver metastases
89. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
90. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients (pts)with metastatic colorectal cancer
91. Multicenter phase II/III study of oxaliplatin plus cyclophosphamide (C) [OXC] versus cisplatin (P) plus cyclophosphamide [CPC] in advanced chemonaive ovarian cancer (AOC) patients (pts): Final results [abstract no. 1502]
92. A multicenter phase II study of oxaliplatin as a single agent in platinum (PT) and/or taxanes (TX) pretreated advanced ovarian cancer (AOC): Final results
93. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
94. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
95. Feasibility study of the paclitaxel, oxaliplatin and cisplatin combination in advanced ovarian cancer patients [abstract no. 1409]
96. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
97. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
98. Eloxatine(Rm) (oxaliplatin) obtains marketing approval in europe [online]
99. Phase II multicentric trial of oxaliplatin as first line chemotherapy in metastatic colorectal carcinoma
100. Phase II randomized study of oxaliplatin (L-OHP) vs its combination with 5-FU in hormone refractory prostate cancer (HRPC) patients (pts)
101. Preliminary results on the activity of oxaloplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients
102. Early phase II trial of trans-1-diammino cyclohexane oxaliplatin (L-OHP) in malignant mealanoma, advanced ovarian cancer, low grade non-Hodgkin's lymphoma (NHL)
103. Oxaliplatin (L-OHP) activity in anthracycline (ANT)-resistant metastatic breast cancer (MBC) patients
104. A phase II study of oxaliplatin (Oxa) and 5-fluorouracil (Fu) in advanced/metastatic breast carcinoma (Abc) patients (pts) previously treated with taxanes (T): Preliminary results [abstract no. 609]
105. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC) [abstract no. 443]
106. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck
107. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
108. The combination of Raltitrexed (Tomudex) and Oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study [abstract no. 2276]
109. Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC) [abstract no. 1018]
110. Update of the oxaliplatin (L-OHP)/navelbine (NVB) phase I/II multicentric trial in patients (pts) with advanced non small cell lung cancer (NSCLC)
111. Oxaliplatin in practice
112. Oxaliplatin (L-OHP): Global safety in 682 patients
113. Phase I study of oxaliplatin in patients with advanced cancer
114. Oxaliplatin reintroduction in patients pretreated with leucovorin (LV), 5-FU and oxaliplatin for metastatic colorectal cancer. A Gercor Study [abstract no. 990]
115. Oxaliplatin induced neuropathy: Could Gabapentin be the answer? [abstract no. 2397]
116. Comparative audiometric evaluation in patients (pts) with advanced squamous cell carcinoma of head and neck (SCHNN) treated with oxaliplatin (L-OHP, transplatin) or cisplatin (CDDP)
117. Anaphylaxis after oxaliplatin
118. Severe anaphylactic reactions to oxaliplatin
119. Promising therapeutic potential of Oxaliplatin + Raltitrexed in patients with advanced colorectal cancer (ACC): Results of a phase I/II trial [abstract no. 997]
120. Phase I-II study of irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hours continuous infusion (C.I.) in metastatic colorectal cancer patients [abstract no. 1161]
121. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin
122. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin
123. Where do we stand with 5-fluorouracil?
124. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer evidence in terms of response rate
125. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
126. Setting a new standard - Irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two phase III studies and implications for clinical practice
127. Raltitrexed: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
128. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
129. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
130. Irinotecan combined with flourouracil compared with flouruoracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. [published erratum appears in Lancet 2000 Apr 15; 355(92120:1372]
131. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials
132. Responses to salvage chemotherapy in advanced ovarian cancer: A critical need for precise definitions of the treated population
133. Cisplatin/carboplatin cross-resistance in ovarian cancer
134. Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest Oncology Group study
135. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex
136. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer
137. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer
138. Treatment of refractory and recurrent ovarian cancer
139. Chemotherapy of advanced ovarian cancer